PTGX
Protagonist Therapeutics Inc
2 of the 83 super-investors we track hold PTGX, worth a combined $28M per their latest 13F filings. The largest position: Stanley Druckenmiller at 0.6% of their portfolio. This quarter the cohort logged 1 buy and 0 sells on the name. Conviction score: 42 of 100 (how strongly the cohort backs it) — ranked #106 of 742 stocks. Conviction easing: 1 fewer super-investor hold it than in 2026Q1.
Why super-investors own PTGX
PTGX is held by 2 super-investors in our cohort, with a combined position value of $28M. The highest-conviction owner is Stanley Druckenmiller at 0.6% of their portfolio. Cohort ownership has shrunk from 3 to 2 over the last four quarters — net interest is fading. This quarter the cohort registered 1 added.
AI-synthesized from 13F filings. Not investment advice.
Cohort owners over time
2018Q1 → 2026Q2How many of the cohort members held this stock each quarter.
Owners (2) · click any column to sort
| #↑ | Manager | % Port. | History | Value | Shares |
|---|---|---|---|---|---|
| 1 | Stanley Druckenmiller | 0.6% | 4q | $26M | 208,900 |
| 2 | Polen Capital Management | <0.1% | 5q | $3M | 22,651 |
Owners of PTGX also hold
Recent activity (1)
| Manager | Move | % Port. | Δ Shares | Value | Filed |
|---|---|---|---|---|---|
| Stanley Druckenmiller | ADD | 0.6% | +31% | $26M | Aug 14, 2026 |
Long US equity 13F-HR filings only. CUSIP 74366E102. Not investment advice.